Susquehanna International Group
NMRA icon

Susquehanna International Group’s Neumora Therapeutics NMRA Stock Holding History

Susquehanna International Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.42M Buy
1,240,241
+501,969
+68% +$1.3M ﹤0.01% 5738
2025
Q4 		$1.32M Buy
738,272
+314,028
+74% +$688K ﹤0.01% 6546
2025
Q3 		$772K Buy
424,244
+153,468
+57% +$248K ﹤0.01% 7960
2025
Q2 		$199K Buy
270,776
+88,435
+48% +$67K ﹤0.01% 11216
2025
Q1 		$182K Buy
182,341
+146,060
+403% +$250K ﹤0.01% 11040
2024
Q4 		$385K Sell
36,281
-7,371
-17% -$88.3K ﹤0.01% 9295
2024
Q3 		$577K Sell
43,652
-9,598
-18% -$112K ﹤0.01% 8119
2024
Q2 		$523K Buy
53,250
+41,859
+367% +$433K ﹤0.01% 8154
2024
Q1 		$157K Buy
11,391
+64
+0.6% +$1.03K ﹤0.01% 10862
2023
Q4 		$193K Sell
11,327
-17,507
-61% -$215K ﹤0.01% 10725
2023
Q3 		$407K Buy
+28,834
New +$360K ﹤0.01% 8706

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Susquehanna International Group's NMRA Position: Q1 2026 in Review

Susquehanna International Group increased its Neumora Therapeutics (NMRA) stake by 68% in Q1 2026, buying an estimated $1.3M and bringing the position to 1,240,241 shares worth $2.42M. The position accounts for ﹤0.01% of the portfolio, ranked #5738.

Susquehanna International Group first reported a position in NMRA in Q3 2023 and has held it in 11 quarters since. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Susquehanna International Group held 1,240,241 shares of Neumora Therapeutics worth $2.42M as of Q1 2026.
  • Susquehanna International Group bought 501,969 Neumora Therapeutics shares in Q1 2026, an estimated $1.3M.
  • Neumora Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5738 holding.
  • Susquehanna International Group first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.